Aug 2026· Transplantation and Cellular Therapy· 0 citations· 33 references
Medicine
TL;DR
Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is effective for treating relapsed or refractory B-cell lymphoma; however, its outcomes remain heterogeneous. We conducted a nationwide retrospective registry study in Japan to assess whether pretreatment body mass index (BMI) influences outcomes after CD19-directed CAR T-cell therapy. Among 944 patients with relapsed or refractory B-cell lymphoma treated between 2019 and 2024, BMI was categorized as Low (<18.5 kg/m²; n = 166), Normal (18.5 to 24.9 kg/m²; n = 619), or High (≥25 kg/m²; n = 159). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), cumulative incidence of relapse or progression (CIR), non-relapse mortality (NRM), and CAR T-cell-related toxicities. Six-month OS rates in the low, normal, and high BMI groups were 73.2%, 83.7%, and 89.3%, respectively (P < .01), and corresponding PFS was 62.3%, 75.6%, and 77.7% (P < .01). CIR was more frequent in the Low-BMI group, whereas NRM did not differ significantly across groups. In the overall cohort, Low-BMI was associated with shortened OS and PFS and higher CIR in multivariable analyses. In a complete-case sensitivity analysis restricted to patients with available disease status data at the time of infusion, these associations were attenuated after adjusting for disease status. Severe CAR T-cell-related toxicities were comparable across BMI groups. Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.
Outcomes after CAR-T failure in LBCL remain poor despite the availability of multiple salvage treatment strategies, and time to relapse after CAR-T therapy was the strongest prognostic factor.
Smith Kungwankiattichai, Sanjog Bastola, Manoj Rai et al.· Transplantation and Cellular...· 0 citations
Higher pretreatment BMI was associated with longer adjusted OS and PFS in patients receiving ICI therapy, with the most consistent favorable association observed for obesity, warranting cautious interpretation.
Si-Yu Sun, Jun-Hao Zhang, Yan Li et al.· Frontiers in Immunology· 0 citations
TyG-BMI is an independent prognostic factor in DLBCL that refines IPI-based stratification, and elevated pre-infusion TyG-BMI is associated with attenuated CAR-T cell persistence and inferior outcomes.
Ze-Lin Liu, Rui-Jun Yang, Jia-Wen Chen et al.· Frontiers in Oncology· 0 citations
The efficacy of CAR T-cell therapy in patients with R/R HGBCL remains suboptimal, and high-grade morphology may help identify patients at particularly high risk of poor outcomes following CAR T-cell therapy.
T. Ochi, S. Makita, Anna Hiratsuka et al.· International Journal of Cli...· 0 citations
In conclusion, CAR‐T therapy offers similar efficacy and safety in R/R B‐ALL patients regardless of CNS involvement, and consolidative allo‐HSCT as consolidation post‐CAR‐T as an independent protective factor for improved EFS and OS in CNSL patients.
Yang-Hong Yu, Hui Xu, Lei Xue et al.· Cancer Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.